Drug intelligence / Profile preview

citalopram + triiodothyronine

Development stage: Preclinical
Lead developer: Lundbeck
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of citalopram, a selective serotonin reuptake inhibitor (SSRI), and triiodothyronine (T3), a thyroid hormone. This combination is used as an augmentation strategy for treating depression, particularly in patients who have not responded adequately to SSRI treatment alone. The addition of T3 to citalopram may enhance antidepressant effects and lead to faster treatment response in some patients.

Targets

SERT allosteric site (Serotonin transporter allosteric site)

Beyond the preview

Go deeper on citalopram + triiodothyronine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on citalopram + triiodothyronine.

Explore the full profile